bioRxivCancer Biology
Reinforcement learning derived chemotherapeutic schedules for robust patient-specific therapy
Abstract
The in-silico development of a chemotherapeutic dosing schedule for treating cancer relies upon a parameterization of a particular tumour growth model to describe the dynamics of the cancer in response to the dose of the drug. In practice, it is often prohibitively difficult to ensure the validity of patient-specific parameterizations of these models for any particular patient. As a result, sensitivities to these particular parameters can result in therapeutic dosing schedules that are optimal in principle not performing well on particular patients. In this study, we demonstrate that chemotherapeutic dosing strategies learned via reinforcement learning methods are more robust to perturbations in patient-specific parameter values than those learned via classical optimal control methods. By training a reinforcement learning agent on mean-value parameters and allowing the agent periodic access to a more easily measurable metric, relative bone marrow density, for the purpose of optimizing dose schedule while reducing drug toxicity, we are able to develop drug dosing schedules that outperform schedules learned via classical optimal control methods, even when such methods are allowed to leverage the same bone marrow measurements.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chemotherapy dose scheduling via Q-learning in a Markov tumor model
M. Giles, Paul K. Newton·bioRxiv·Jun 5, 2025
- A Mathematical Framework for Comparison of Intermittent and Continuous Adaptive Chemotherapy Dosing in Cancer
Cordelia D. McGehee, Yoichiro Mori A·npj Systems Biology and ApplicationsPeer-reviewed·Nov 29, 2024
- Optimal Chemotherapy Scheduling for Non-Genetic Drug Resistance
Sasan Paryad-Zanjani, Michael Saint-Antoine, Abhyudai Singh·bioRxiv·May 11, 2021
- Personalized therapy design for liquid tumors via optimal control theory
Fabrizio Angaroni, Alex Graudenzi, … Marco Antoniotti·bioRxiv·Jun 7, 2019
- Quantification of long-term doxorubicin response dynamics in breast cancer cell lines to direct treatment schedules
G. Howard, T. A. Jost, … A. Brock·bioRxiv·May 24, 2021
- Gaming the cancer-immunity cycle by synchronizing the dose schedules
Saeedeh Mahmoodifar, K. Stuckey, Paul K. Newton·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 8, 2025